Literature DB >> 20731201

Why chemotherapy can fail?

M Król1, K M Pawłowski, K Majchrzak, K Szyszko, T Motyl.   

Abstract

There are many reasons that lead to failure of cancer chemotherapy. Cancer has the ability to become resistant to many different types of drugs. Increased efflux of drug, enhanced repair/increased tolerance to DNA damage, high antiapoptotic potential, decreased permeability and enzymatic deactivation allow cancer cell survive the chemotherapy. Treatment can lead to the death of most tumor cells (drug-sensitive), but some of them (drug-resistant) survive and grow again. These tumor cells may arise from stem cells. There are many studies describing human experiments with multidrug resistance, especially in breast cancer. Unfortunately, studies of canine or feline ABC super family members are not as extensive as in human or mice and they are limited to several papers describing PGP in mammary cancer, cutaneous mast cell tumors and lymphoma. Multidrug resistance is one of the most significant problems in oncology today. The involvement of many different, not fully recognized, mechanisms in multidrug resistance of cancer cells makes the development of effective methods of therapy very difficult. Understanding the mechanisms of drug resistance in cancer cells may improve the results of treatment. This review article provides a synopsis of all aspects that refer to cancer cell resistance to antitumor drugs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20731201

Source DB:  PubMed          Journal:  Pol J Vet Sci        ISSN: 1505-1773            Impact factor:   0.821


  13 in total

Review 1.  Targeting mitochondrial metabolism for metastatic cancer therapy.

Authors:  Antonino Passaniti; Myoung Sook Kim; Brian M Polster; Paul Shapiro
Journal:  Mol Carcinog       Date:  2022-06-20       Impact factor: 5.139

2.  Toxicity assessments of selected trichloroethylene and perchloroethylene metabolites in three in vitro human placental models.

Authors:  Elana R Elkin; Anthony L Su; Brian A Kilburn; Kelly M Bakulski; D Randall Armant; Rita Loch-Caruso
Journal:  Reprod Toxicol       Date:  2022-03-16       Impact factor: 3.421

3.  Characterization of a multiple endogenously expressed adenosine triphosphate-binding cassette transporters using nuclear and cellular membrane affinity chromatography columns.

Authors:  K-L Habicht; N S Singh; M A Khadeer; R Shimmo; I W Wainer; R Moaddel
Journal:  J Chromatogr A       Date:  2014-03-05       Impact factor: 4.759

4.  A hederagenin saponin isolated from Clematis ganpiniana induces apoptosis in breast cancer cells via the mitochondrial pathway.

Authors:  Lin Cheng; Liang Shi; Jing Wu; Xujie Zhou; Xiaoxia Li; Xi Sun; Lei Zhu; Tian-Song Xia; Qiang Ding
Journal:  Oncol Lett       Date:  2017-11-27       Impact factor: 2.967

5.  Unexpected Lower Expression of Oncoprotein Gankyrin in Drug Resistant ABCG2 Overexpressing Breast Cancer Cell Lines

Authors:  Taheri Taheri; Khadijeh Jamialahmadi; Fatemeh Khadijeh
Journal:  Asian Pac J Cancer Prev       Date:  2017-12-29

6.  Synergistic Activity of Paclitaxel, Sorafenib, and Radiation Therapy in advanced Renal Cell Carcinoma and Breast Cancer.

Authors:  Kyung Hwa Choi; Jeong Yong Jeon; Young-Eun Lee; Seung Won Kim; Sang Yong Kim; Yeo Jin Yun; Ki Cheong Park
Journal:  Transl Oncol       Date:  2018-12-03       Impact factor: 4.243

7.  Long non-coding RNA LSINCT5 inactivates Wnt/β-catenin pathway to regulate MCF-7 cell proliferation and motility through targeting the miR-30a.

Authors:  Guizhi Zhang; Wenbo Song
Journal:  Ann Transl Med       Date:  2020-12

8.  Gene expression profiles in canine mammary carcinomas of various grades of malignancy.

Authors:  Karol M Pawłowski; Henryk Maciejewski; Izabella Dolka; Jan A Mol; Tomasz Motyl; Magdalena Król
Journal:  BMC Vet Res       Date:  2013-04-15       Impact factor: 2.741

9.  Expression and role of PGP, BCRP, MRP1 and MRP3 in multidrug resistance of canine mammary cancer cells.

Authors:  Karol M Pawłowski; Joanna Mucha; Kinga Majchrzak; Tomasz Motyl; Magdalena Król
Journal:  BMC Vet Res       Date:  2013-06-17       Impact factor: 2.741

10.  Piperlongumine inhibits migration and proliferation of castration-resistant prostate cancer cells via triggering persistent DNA damage.

Authors:  Ding-Fang Zhang; Zhi-Chun Yang; Jian-Qiang Chen; Xiang-Xiang Jin; Yin-da Qiu; Xiao-Jing Chen; Hong-Yi Shi; Zhi-Guo Liu; Min-Shan Wang; Guang Liang; Xiao-Hui Zheng
Journal:  BMC Complement Med Ther       Date:  2021-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.